Helix Technologies, Inc. (OTCQB:HLIX) and Medical Outcomes Research Analytics, LLC (MOR Analytics) announced Saturday they have entered into an agreement to combine, creating an innovative healthcare information, analytics and technology organization. Helix’s industry-leading compliance and point of sale technologies are tailored to the unique needs of the quickly evolving cannabis industry, offering customers seamless compliance management solutions and earning government contracts in this rapidly growing market. MOR Analytics, founded in 2019, is an innovative and evolving private company developing a Real World Evidence (“RWE”) and Software as a Service (“SaaS”) analytics platform designed to support the information requirements of constituents across the healthcare industry.
Vireo Health International, Inc. (“Vireo” or the “Company”) (CNSX: VREO, OTCQX: VREOF), the science-focused, multi-state cannabis company with active operations in exclusively medical-only markets and licenses in seven states and the Commonwealth of Puerto Rico, today announced that it has reached a definitive agreement with Ayr Strategies Inc. (CSE:AYR.A)(OTCQX:AYRSF), to sell all of the assets and liabilities of its affiliated company, Ohio Medical Solutions, LLC (“OMS”), for total consideration of $4.85 million.
Kadenwood, LLC, a consumer seed-to-shelf CBD company dedicated to fostering trust and transparency in the mainstream wellness category, announced today the acquisition of EcoGen Laboratories, the leading global manufacturer and supplier of hemp-derived CBD materials and formulations. The deal effectively establishes Kadenwood as the largest supplier of vertically-integrated, hemp-derived cannabidiol (CBD) in the US, expanding the company’s ability to scale production of its quality-driven CBD products.
PAO Group, Inc. (OTC Pink: PAOG) has announced the acquisition of RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a treatment for Chronic Obstructive Pulmonary Disease (COPD) under development that is derived from a patented cannabis extraction method. A patent application on the RespRx formulation for symptoms associated with COPD and other similar respiratory conditions has been filed. A trademark on the name RespRx as the brand name for its CBD formulation to treat the symptoms associated with COPD and other similar respiratory conditions has also been filed. The acquisition is part of PAOG’s overall medical cannabis revitalization strategy. Earlier on Tuesday this week, PAOG announced the acquisition of a cannabis cultivation operation developing a proprietary cannabis cultivar from Puration, Inc. (OTC Pink: PURA).
Schultze Special Purpose Acquisition Corp. (NASDAQ: SAMA, SAMAW, and SAMAU) (“SAMA”) and Clever Leaves International Inc. (“Clever Leaves” or the “Company”) jointly announced today that they have entered into a definitive agreement (the “Business Combination Agreement”), pursuant to which a newly formed holding company, Clever Leaves Holdings Inc., will acquire SAMA and Clever Leaves and is anticipated to become a NASDAQ-listed public company trading under the ticker symbol “CLVR” with an anticipated initial enterprise value of approximately $255 million.
PAO Group, Inc. (USOTC: PAOG) today announced the company’s senior management team has acquired majority control of the company. The current Chief Executive Officer (CEO), James, C. DiPrima, leading a strategic team of managers, has purchased from a third party, preferred stock holding majority voting rights. Mr. DiPrima plans to remain as CEO. The management team has designed a revitalized medical cannabis strategy involving two planned acquisitions anticipated to be finalized in the coming weeks. “I am enthusiastic about PAOG’s revitalization initiative to move forward again on its original mission to provide patient care alternatives to traditional patient care solutions,” said CEO James C. DiPrima. “As part of our overall medical cannabis strategy, we are committed to mitigating the opioid epidemic by providing appropriate medical cannabis alternatives.”
Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCQX: JUSHF), a globally-focused, multi-state cannabis and hemp operator, announced the closing of the Company’s previously announced acquisition of 80 percent of the economic and voting interests in Agape Total Health Care Inc. (“Agape”), a Pennsylvania Dispensary Permittee. In closing, Jushi acquired a majority interest in Agape, who will open three retail locations: one in the Philadelphia region, one in Reading and one in Pottsville. With the closing of this deal and prior announced acquisitions, Jushi’s subsidiaries will have rights to operate up to 15 dispensaries, the current maximum number of permitted retail locations in the Commonwealth outside of the Clinical Registrant Program.
Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCQX: JUSHF), a globally-focused, multi-state cannabis and hemp operator, has reached a definitive binding agreement (the “Agreement”) to acquire 100% of the equity of Pennsylvania Medical Solutions, LLC (the “Permittee”), a Pennsylvania grower-processor owned by Vireo Health International, Inc. (“Vireo”) (CNSX: VREO; OTCQX: VREOF) (the “Proposed Acquisition”). The Permittee operates a 90,000 sq. ft. facility with approximately 45,000 sq. ft. of high-quality, indoor cultivation when construction is complete. The Permittee’s property can further accommodate an additional 25,000 sq. ft. of indoor cultivation bringing the total to 70,000 sq. ft. The Proposed Acquisition will solidify Jushi’s leadership position in Pennsylvania by adding equity ownership of Permittee, with its large-scale, high-quality, indoor cannabis cultivation and processing capabilities, to its other subsidiaries’ collective rights to operate up to 15 dispensaries.
Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or “the Company”), one of the largest vertically integrated multi-state cannabis operators in the United States, announced Tuesday that it has entered into agreements with Verdant Creations, LLC and its affiliates (collectively “Verdant”) that will give Cresco the option to purchase four additional Ohio dispensaries (the “Dispensaries”) currently operated by Verdant (the “Transaction”). Completion of the Transaction is subject to approval by the Ohio Board of Pharmacy and, upon closing, Cresco will have a total of five dispensaries in Ohio Ð the maximum allowed by the State. Verdant currently operates dispensaries in Cincinnati, Chillicothe, Marion, Newark, and Columbus, Ohio. The Columbus location is not part of the Transaction.
Pressure BioSciences Inc (OTCQB:PBIO), which is merging with Cannaworx Inc and SkinScience Labs Inc to become Availa Bio, announced Tuesday that Cannaworx is expanding its sales and distribution network by signing a letter of intent to acquire Louisiana-based Five Leaf Labs (FLL). The company said the expansion comes at a “critical time” for Cannaworx as it is gearing up for the market launch of its first two products over the coming few weeks. In a statement, Five Leaf Labs founder and president Keyon Janani said the company’s hemp-derived, CBD products are made exclusively from organic, pesticide-free hemp. “All existing and pipeline products are focused entirely on the medicinal properties of CBD. We recently released our first set of CBD-infused products to the US market, which were greeted with excellent, widespread acceptance,” Janani added.
What We Do
Who We Are
How We Work
Who We Help
Get In Touch
Connect With Us
Subscribe to Our Daily Note
We publish a Daily Note that aggregates M&A activity, notable developments, regulatory changes, and conferences we deem to be of interest to our partners. It is a quick afternoon read and an easy way to keep your finger on the pulse of the healthcare space. Please fill in your name and email address below if you wish to subscribe.